Commercial With oral obesity race underway, all eyes are on Lilly’s Foundayo launch BioSpaceNovo Nordisk's oral Wegovy has a few months' head start on Eli Lilly's newly approved pill.CommercialMetabolic & GLP-1Read full story pharminent April 10, 2026 (Last updated: April 10, 2026) BioSpace Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill. CommercialMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Senju launches first-in-class dry eye disease drug in JapanNext: RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders Related Stories Commercial Post-marketing oncology studies: Enabling faster recruitment and lower costs pharminent June 22, 2026 Commercial The first 14 days: How specialty programs set patients up for success pharminent June 22, 2026 Commercial Denali sells FDA voucher for $195M to support neurodegenerative pipeline pharminent June 19, 2026
